NEW YORK, Feb 6 – Toronto-based proteomics company Syn X Pharma has appointed Bradley Thatcher as vice president of proteomics discovery, Syn X said Tuesday.
Prior to joining Syn X, Thatcher was a senior field scientist specializing in proteomics and director of special projects for Ciphergen Biosystems of Fremont, Calif., where he designed systems to identify, purify, characterize and sequence proteins for development as drug candidates
Thatcher will head the discovery activities of Syn X's proteomics program, cataloging the protein changes involved in disease, the company said.
" Syn X's ability to attract a candidate of Dr. Thatcher's caliber demonstrates our commitment to being a leader in proteomics ," Sean McNicholas, Syn X CEO, said in a statement.
Syn X's flagship product, the Proteomics Discovery Platform, can be used in pre-clinical and clinical phases to identify responders and non-responders to a particular drug, or to identify patients who will benefit from a medicine earlier in the course of a disease.
The company currently has several diagnostics in development for cardiovascular diseases including heart failure, hypertension, and diabetes, and central nervous system diseases such as Alzheimer's disease.